Neurogenetic correlates of Parkinson's disease: Apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism

Neuroscience Letters

Volumn 266, Issue 2, 1999, Pages 149-151

  Bon, M A M ^a   Jansen Steur, E N H ^a   De Vos, R A I ^b   Vermes, I ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b Laboratory for Pathology   (Netherlands)

Author keywords

Apolipoprotein E; Cytochrome P450 2D6; Genetic polymorphism; Morphological confirmed Parkinson's disease; Progression of Parkinson's disease

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450;

ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0033532119     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00278-5     Document Type: Article

References (13)

1. Ballering L.A.P., Steffens-Nakken H.M., Esselink R.A.J., de Vos R.A.I., Jansen Steur E.N.H., Vermes I. Apolipoprotein E genotyping in patients with neurogenerative diseases. Clin. Biochem. 30:1997;405-411.
2. Bandmann O., Marsden C.D., Wood N.W. Genetic aspects of Parkinson's disease. Mov. Disord. 13:1998;203-211.
3. Checkoway H., Farin F.M., Costa-Mallen P., Kirchner S.C., Costa L.G. Genetic polymorphism in Parkinson's disease. NeuroToxicology. 19:1998;635-644.
4. Douglas A.M., Atchison B.A., Somogyi A.A., Drummer O.H. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics. 4:1994;154-158.
5. Hardy J., Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science. 282:1998;1075-1079.
6. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184.
7. Kontula K., Setälä K.A., Kuusi T., Hämäläinen L., Syvänen A.C. Apolipoprotine E polymorphism determined by restriction enzyme analysis of DNA amplified by PCR. Clin. Chem. 36:1990;2087-2092.
8. Lang A.E., Lozano A.M. Parkinson's disease, first of two parts. N. Eng. J. Med. 339:1998;1044-1053.
9. Price D.L., Sisodia S.S., Borchelt D.R. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 282:1998;1079-1083.
10. Riedl A.G., Watts P.M., Jenner P., Marsden C.D. P450 Enzymes and Parkinson's disease: the story so far. Mov. Disord. 13:1998;212-220.
11. Siest G., Pillot T., Regis-Bailly A., Leininger-Muller B., Steinmetz J., Galteau M.M., Visvikis S. Apolipoprotein E: important gene and protein to follow in laboratory medicine. Clin. Chem. 41:1995;1068-1086.
12. Steijns S.W., Weide van der J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin. Chem. 44:(5):1998;1-4.
13. Vos de R.A.I., Jansen E.N.H., Stam F.C., David R., Swaab D.F. 'Lewy body disease': clinicopathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin. Neurol. Neurosurg. 97:1995;13-22.